Company Filing History:
4 out of 2,890 
2 out of 8,373 
2 out of 443 
Years Active: 2012-2018
Title: Innovations of Kenneth Tanabe: Pioneering Cancer Research
Introduction
Kenneth Tanabe, based in Brookline, Massachusetts, is a notable inventor recognized for his contributions to cancer research. With a portfolio of four patents, Tanabe’s work primarily focuses on identifying cancer-related extracellular matrix signatures and developing methods and products aimed at enhancing cancer detection, diagnosis, and treatment.
Latest Patents
Tanabe's recent patents encompass groundbreaking advancements in proteomic methods geared toward identifying cancer-related proteins. His innovations include techniques and kits that utilize cancer-specific extracellular matrix proteins, which play critical roles in various aspects of cancer pathology. These patents detail panels or signature sets of proteins that are instrumental in detecting, diagnosing, and treating cancers, as well as monitoring therapeutic progress in patients. Furthermore, his work highlights the identification of these proteins through proteomics analysis of tissue samples from cancer patients, with particular emphasis on their utility in colon cancer cases.
Career Highlights
Kenneth Tanabe has made significant strides in his career, contributing to esteemed institutions such as The General Hospital Corporation and the Massachusetts Institute of Technology (MIT). His expertise in the intersection of proteomics and oncology has paved the way for enhanced methodologies in cancer treatment and monitoring, establishing him as a vital figure in the field of cancer research.
Collaborations
Throughout his career, Tanabe has collaborated with renowned colleagues, including Richard O. Hynes and Alexandra Naba. These partnerships have further enriched his research endeavors and contributed to the collective understanding and innovation in cancer therapeutics.
Conclusion
Kenneth Tanabe's inventive spirit and dedication to cancer research have resulted in significant advancements within the medical field. His innovative patents underscore the importance of identifying cancer-related proteins and utilizing them in clinical settings, ultimately aiming to improve patient outcomes and therapeutic strategies in oncology.